Partnership formed between Sonrai and AOA Dx to expedite the creation of a test for ovarian cancer diagnosis
In a recent development, Sonrai Analytics and AOA Dx have announced a strategic partnership to advance the development of AOA's ovarian cancer diagnostic test. This collaboration aims to leverage multi-omic data integration from liquid biopsy technology to enhance early detection capabilities for ovarian cancer [1].
AOA Dx, an early-stage biotech company, is focused on creating the first test to diagnose ovarian cancer in symptomatic women. The test leverages a combination of novel gangliosides, lipids, and proteins. Sonrai Analytics, on the other hand, is a PathAI product and will support AOA in validating diagnostic biomarkers, thereby enhancing the accuracy and clinical utility of the test.
Dr Abigail McElhinny, Chief Scientific Officer of AOA Dx, stated that the partnership will allow them to integrate and manage their in-house development data, cross-reference it with public datasets, and analyze it seamlessly within one centralized environment. This will enable AOA to harness Sonrai's cloud-based advanced analytics platform, data infrastructure, and bioinformatic expertise.
Sonrai will offer its bioinformatics expertise, enabling AOA to harness pre-built machine learning tools and run automated pipelines. The Sonrai Discovery platform will enable AOA to store and manage their clinical data securely, with role-based environments, controlled access, workspace isolation, cross-functional collaboration, and real-time performance tracking.
Meanwhile, in another development, b-rayZ has become Affidea's AI Partner for breast imaging. The nature of the partnership between b-rayZ and Affidea was not specified, but it marks a significant step in the integration of AI technology in breast imaging.
In other news, PathAI has received FDA clearance for their AISight Dx platform. This clearance was announced in "Digital Health & AI News". AbbVie, on the other hand, has received marketing authorisation from MHRA, although the specific product was not specified.
This strategic partnership between Sonrai Analytics and AOA Dx, if successful, could transform the pathway for women with ovarian cancer, potentially changing outcomes and offering significant savings to healthcare systems.
[1] Source: Femtech News
- The strategic partnership between Sonrai Analytics and AOA Dx, as reported in Femtech News, could revolutionize the diagnostic process for ovarian cancer, potentially changing outcomes and leading to significant cost savings in healthcare.
- In the realm of digital health and technology, PathAI's AISight Dx platform has recently received FDA clearance, as mentioned in Digital Health & AI News.
- The integration of AI technology in healthcare continues to grow, as evidenced by Affidea partnering with b-rayZ for breast imaging, although the specific details of their partnership have yet to be disclosed.
